GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance.The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Ela ...

Company Overview - NovoCure (NVCR) shares increased by 5.3% to close at $18, supported by higher trading volume compared to normal sessions, following an 11.9% decline over the past four weeks [1][2] Product Development - The rise in stock price is linked to growing investor optimism regarding the development and commercialization of Tumor Treating Fields (TTFields) devices, specifically Optune Gio and Optune Lua, which are approved for treating solid tumor cancers [2] Financial Performance - NovoCure is expected to report a quarterly loss of $0.40 per share, reflecting a year-over-year decrease of 29%. Revenue is anticipated to be $152.48 million, representing a 1.4% increase from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - NovoCure holds a Zacks Rank of 2 (Buy) and is part of the Zacks Medical - Biomedical and Genetics industry. In comparison, Kymera Therapeutics, another company in the same industry, saw a 3.5% decline in its stock price, despite a 51.1% return over the past month [5] - Kymera Therapeutics has experienced a 5.8% increase in its consensus EPS estimate over the past month, now projected at -$0.84, which is a 44.8% decrease from the previous year [6]

Press release Ecully, June 6, 2025 – 6.00 p.m. SPINEWAY Minutes of the General Meeting of June 4, 2025 The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Wednesday, June 4, 2025 at 2:00 p.m at the company’s registered office, 7 allée Moulin Berger in Ecully (69). The defaulting shareholders were represented by SELARL TULIER POLGE ALIREZAI, as ad hoc representative appointed by Order of the President of the Lyon Commercial Court dated April 30, 2 ...

Summary of NovoCure (NVCR) 2025 Conference Call Company Overview - **Company**: NovoCure (NVCR) - **Industry**: Medical Devices, Oncology - **Mission**: Focused on extending survival in aggressive forms of cancer through the development and commercialization of Tumor Treating Fields (TTFields) [2][28] Core Mechanism and Technology - **Tumor Treating Fields**: Electric fields that target dividing cancer cells, leveraging their electrical properties to induce cell death through various mechanisms, including antimitotic effects and immune system activation [3][4] - **Device Components**: The therapy is delivered via a medical device consisting of a field generator and transducer arrays worn by patients [5][6] Financial Performance - **Revenue**: Over $600 million generated from glioblastoma (GBM) treatments, with a solid foundation of more than 4,200 active patients [6][10][13] - **Cash Generation**: The commercial business can generate approximately $100 million in cash annually, which is reinvested into research and development [7] Clinical Trials and Pipeline - **Current Indications**: Established in GBM, with recent FDA approvals for non-small cell lung cancer (NSCLC) and ongoing trials for brain metastases and pancreatic cancer [10][12][19] - **Recent Data**: Positive phase three trial results for pancreatic cancer showing a two-month extension in median overall survival and improved one-year survival rates [14][15] - **Future Trials**: Ongoing trials for GBM and pancreatic cancer, with expectations for additional data releases in the coming year [22][26] Market Expansion and Opportunities - **Total Addressable Market (TAM)**: Potential to expand TAM by 7x over the next two years with new indications [13] - **Combination Therapies**: The device can be used in conjunction with existing therapies, enhancing treatment efficacy [30][31] Regulatory and Commercial Strategy - **Regulatory Filings**: Preparing for FDA submissions for pancreatic cancer and other indications, with anticipated launches in 2026 [16][18] - **Sales Force Utilization**: Leveraging existing sales force for new indications, ensuring efficient market penetration [36][51] Path to Profitability - **Transition Year**: 2025 is viewed as a demand generation year, with expected revenue contributions from new indications in subsequent years [47][48] - **Economies of Scale**: Anticipated cost efficiencies as the company expands its product offerings and market presence [51][53] Key Takeaways - **Unique Positioning**: NovoCure's device-based treatment offers a novel approach to aggressive cancers, with a strong foundation in GBM and expanding into other solid tumors [19][25] - **Positive Reception**: Recent clinical data has generated significant interest and positive feedback from the medical community, indicating strong potential for adoption [39][40] - **Execution Focus**: The company is committed to executing its strategy effectively, with a clear path to profitability and continued investment in its pipeline [28][55]

Zai Lab Limited ZLAB and NovoCure Limited NVCR revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.The data were presented at the 2025 American Society of Clinical Oncology Annual Meeting.The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclita ...

Water Solutions Crude Oil Logistics Investor Presentation May 2025 NYSE: NGL Company Overview NGL Total EBITDA by Segment $661.7 MM(1) $542.0 MM 82% 10% 8% 82% 1. EBITDA values reflect full year Fiscal 2025 and does not include corporate or discontinued operations 2 $66.4 MM 82% 10% 8% Liquids Logistics $53.3 MM 10% 8% ▪ Provides water transportation, treating, recycling, and handling services for upstream customers ▪ Largest integrated water solutions network of injection wells and large diameter pipe in t ...

Company Information - Spineway is engaged in the design, manufacture, and marketing of innovative implants and surgical instruments for treating severe spinal disorders [7] - The company has an international network of over 50 independent distributors, with more than 70% of its revenue generated from exports [7] Upcoming Events - A Combined General Meeting is scheduled for June 4, 2025, at 2:00 p.m. at the Group's headquarters in Ecully [3] - The notice of the meeting, including the agenda and resolutions, was published on April 30, 2025 [4] - The next financial report, detailing H1 2025 revenue, is expected on July 30, 2025 [5] Regulatory Information - Spineway is eligible for PEA-SME (Equity Savings Plans for SMEs), which may attract certain investors [6] - All preparatory documents for the General Meeting can be accessed on the company's website under "Investors/Regulated Information" [5]

Core Viewpoint - Team, Inc. reported mixed results for Q1 2025, with strong performance in the Inspection and Heat Treating (IHT) segment offset by weakness in the Mechanical Services (MS) segment, while the company is optimistic about future growth driven by strategic initiatives and operational improvements [13]. Financial Performance - Total revenues for Q1 2025 were $198.7 million, slightly down from $199.6 million in the same quarter of 2024 [2]. - The net loss widened to $29.7 million, or $6.61 per share, compared to a loss of $17.2 million, or $3.89 per share, in Q1 2024 [2]. - Adjusted EBITDA decreased to $5.3 million from $6.5 million year-over-year, with the margin narrowing to 2.7% from 3.3% [2]. Segment Performance - The IHT segment saw revenues rise by 6.8% year-over-year to $106.2 million, driven by an 8.8% increase in U.S. operations and a 39% improvement in adjusted EBITDA [3]. - The MS segment experienced a 7.7% revenue decline to $92.4 million, resulting in an operating loss of $1.1 million, down from an income of $4.1 million in the prior year [4]. Cost Management - The company-wide gross margin decreased to 23.8% from 24.4%, while SG&A expenses fell by 3.4% to $53.3 million, indicating modest operational efficiencies [5]. - Management initiated a cost optimization initiative targeting annualized savings of at least $10 million [9]. Management Insights - CEO Keith Tucker noted that Q1 results were impacted by seasonality and severe winter weather, but expressed confidence in robust activity levels for Q2 and full-year growth expectations [6]. - CFO Nelson Haight highlighted consistent execution and improving performance as key factors in the recent refinancing deal, with expectations for continued annual improvement in adjusted EBITDA [7]. Strategic Initiatives - The company completed a refinancing in March 2025, extending loan maturities to 2030 and lowering the blended interest rate by over 100 basis points, which improved financial flexibility [12]. - Management reaffirmed its commitment to achieving at least 15% growth in adjusted EBITDA for the full year, supported by margin improvements and steady revenue gains [10][11].

Core Insights - Team, Inc. reported its financial results for the first quarter of 2025, highlighting a total revenue of $198.7 million, which is essentially flat compared to the prior year period [4][6][9] - The Inspection and Heat Treating (IHT) segment showed strong growth with a revenue increase of 6.8% year-over-year, while the Mechanical Services (MS) segment experienced a decline of 7.7% [4][12][29] - The company reported a net loss of $29.7 million for the first quarter, which includes an $11.9 million loss on debt extinguishment due to refinancing [7][9][22] Financial Performance - First quarter revenues totaled $198.7 million, with a gross margin of 23.8%, down from 24.4% in the prior year [6][22] - Adjusted EBITDA for the first quarter was $5.3 million, representing 2.7% of consolidated revenue, compared to $6.5 million (3.3% of revenue) in the prior year [9][22] - Selling, general, and administrative expenses decreased by 3.4% to $53.3 million compared to the first quarter of 2024 [7][22] Segment Analysis - The IHT segment generated revenues of $106.2 million, up 6.8% from $99.4 million in the prior year, driven by increased activity in turnaround services and capital projects [12][29] - The MS segment's revenues fell to $92.4 million from $100.2 million, primarily due to lower callout activity and project delays [12][29] - Operating income for the IHT segment increased by 67.7% to $8.7 million, while the MS segment reported an operating loss of $1.1 million [13][29] Strategic Initiatives - The company completed a refinancing transaction in March 2025, which lowered its blended cost of capital and extended term debt maturities to 2030 [4][7] - An optimization program was launched to improve workforce utilization and cost efficiency, expected to yield annualized cost savings of at least $10 million [4][5] - The leadership team is focused on generating top-line growth and improving cash flow generation while navigating market uncertainties [5][4] Balance Sheet and Liquidity - As of March 31, 2025, the company had total liquidity of $29.1 million, including $12.8 million in cash and cash equivalents [14][15] - Total debt increased to $353.6 million from $325.1 million at the end of 2024, primarily due to the refinancing and higher borrowings [15][14] - The company's net debt was reported at $336.8 million as of March 31, 2025 [15]

SUGAR LAND, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today announced that it will issue its first quarter 2025 earnings release on Monday, May 12, 2025 after the close of trading on the New York Stock Exchange. TEAM will host a conference call to discuss its fina ...